Mises à jour impartiales et pratiques en psychopharmacologie

PUBLICATIONS RÉCENTES

Quick Take Vol. 91

0,75 CMEs
Comment les œstrogènes et le statut hormonal influencent-ils le traitement de la psychose chez la femme ? Quel agoniste du GLP-1 est le plus efficace contre la prise de poids induite par les antipsychotiques ? Les antipsychotiques de nouvelle génération surpassent-ils l’aripiprazole dans le maintien du trouble bipolaire ? Le lithium à faible dose ralentit-il le déclin dans le trouble cognitif léger ? Quand la thérapie cétogène est-elle raisonnable dans les troubles mentaux sévères ?
Experts: Amanda Koire, M.D., Ph.D., Oliver Freudenreich, M.D., F.A.C.L.P., James Phelps, M.D., Scott R. Beach, M.D., Derick E. Vergne, M.D.
41,37 minutes réparties en 5 sections audio

Effets indésirables cardiaques des médicaments psychiatriques

1,25 CMEs
Une revue pratique des effets indésirables cardiaques des médicaments psychiatriques : modifications de la fréquence cardiaque et de la pression artérielle, prolongation du QT avec les antipsychotiques et les antidépresseurs, recommandations concernant l’halopéridol IV, surveillance de la myocardite et de la cardiomyopathie induites par la clozapine, innocuité des médicaments indiqués dans le TDAH, et cadre d’évaluation du rapport bénéfice-risque pour la surveillance par ECG au-delà des seuils rigides de QTc.
Scott R. Beach, M.D.
Harvard Medical School
75,59 minutes réparties en 11 sections

Actualisation d’août 2026 : centanafadine, oveporexton, et nouvelles recommandations sur le TOC, le lithium et l’insomnie

0,75 CMEs
Ce guide traite des deux approbations « first-in-class » de la mi-2026, la centanafadine dans le TDAH et l’oveporexton dans la narcolepsie de type 1, ainsi que des nouvelles recommandations sur les seuils posologiques dans le TOC, des lithémies qui conditionnent le risque rénal et du classement par l’AASM de la TCC-I face au traitement combiné dans l’insomnie chronique.
Sebastián Malleza, M.D.
Psychopharmacology Institute
Voir plus d'informations

Quick Take Vol. 90

0,75 CMEs
L’exposition prénatale aux antidépresseurs cause-t-elle l’autisme ou le TDAH chez les enfants ? Comment évaluer le risque cardiaque lors de l’association d’un antipsychotique et d’un SSRI ? Dans quels cas réintroduire la clozapine après un épisode de neutropénie ? Faut-il renommer la schizophrénie ? L’ajout d’ashwagandha à la mélatonine améliore-t-il le sommeil davantage que chacun de ces agents utilisé seul ?
Experts: Amanda Koire, M.D., Ph.D., Scott R. Beach, M.D., Oliver Freudenreich, M.D., F.A.C.L.P., Derick E. Vergne, M.D.
47,15 minutes réparties en 5 sections audio

Pharmacothérapie de l’insomnie chronique : un guide pratique

1,0 CMEs
Un guide pratique de la prise en charge pharmacologique de l’insomnie chronique. Le Dr Kolla passe en revue les antagonistes doubles des récepteurs aux orexines, les médicaments de type Z, les benzodiazépines, la mélatonine et le ramelteon, les antidépresseurs sédatifs et les antipsychotiques, avec des recommandations pour la grossesse, les personnes âgées et le traitement au long cours.
Bhanu Prakash Kolla, M.D.
Mayo Clinic
55,07 minutes réparties en 11 sections

Hyponatrémie induite par les antidépresseurs : mécanismes, risques, diagnostic et prise en charge

0,50 CMEs
Ce guide propose aux prescripteurs une approche fondée sur les preuves de l’hyponatrémie associée aux antidépresseurs : comment se développe le syndrome d’antidiurèse inappropriée (SIAD), quels patients surveiller et à quel moment, comment reconnaître les symptômes susceptibles de mimer une dépression, et comment prendre en charge le trouble puis appliquer les stratégies de substitution.
Sebastián Malleza, M.D.
Psychopharmacology Institute
Voir plus d'informations

Explorez notre vaste bibliothèque de vidéos, de résumés de recherche et d’entretiens avec des experts.

CME Information

Physicians – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Download Accreditation Information (PDF)

Nursing professionals – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The ANCC accepts AMA PRA Category 1 Credit(s)™ as Contact Hours, under this calculation: 1 CME = 1 Contact Hour. 

All of our content is psychopharmacology, so the pharmacology hours shown on your certificate match the credits awarded for that activity. Your certificate states them on their own line, separately from the credit designation statement.

This applies to APRN pharmacology renewal as well. Boards of nursing define pharmacology CE in their own way, so please confirm with your board that this is the documentation they expect.

Download Accreditation Information (PDF)

Physician assistants – CME Accreditation Statement

The activities below have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy LLC is accredited by the ACCME to provide continuing medical education for physicians.

Medical Academy, LLC designates each enduring material for the number of AMA PRA Category 1 Credits™ listed below. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The NCCPA accepts AMA PRA Category 1 Credit™ from providers accredited by the ACCME toward PA certification maintenance. Requirements are set by the NCCPA, so please confirm with them what your current cycle requires.

Download Accreditation Information (PDF)

Physicians outside the United States – CME Accreditation Statement

AMA PRA Category 1 Credit™ may be awarded to any physician, whether or not they are licensed in the United States. The requirements are the same.

The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu.

Whether these credits count toward your own national continuing education requirement is decided by your national medical chamber or society, and the rules differ from country to country. We recommend confirming with them before relying on the credits for a licensing or recertification requirement.

Self Assessment for MOC – Accreditation Statement
  • Psychopharmacology Institute Self-Assessment Program 2026

Dates: April 1, 2026 – April 1, 2029

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2026 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2025

Dates: April 1, 2025 – April 1, 2028

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2025 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

  • Psychopharmacology Institute Self-Assessment Program 2024

Dates: April 1, 2024 – April 1, 2027

The American Board of Psychiatry and Neurology has reviewed the Psychopharmacology Institute Self-Assessment Program 2024 and has approved this activity as part of a comprehensive Self-Assessment activity, which is mandated by the ABMS as a necessary component of Continuing Certification.

Vous vous sentez perdu au début de votre résidence en psychiatrie ?

Accédez à TOUS nos produits GRATUITEMENT pendant 3 mois !